Clinical Trial Update: Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 study evaluating siponimod (Mayzent) for its effects on microglia in secondary progressive multiple sclerosis has been terminated with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• MAYZENT (siponimod)

Snippet

Sponsor: State University of New York at Buffalo | Conditions: Secondary-progressive Multiple Sclerosis | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2025-05-13